Molecular therapy for muscle atrophy and wasting: Cilostazol, a phosphodiesterase inhibitor used in the treatment of Peripheral vascular disease, increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors  genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 1/December/2017, 12.03 am

Natural product-based therapy for body weight control, energy homeostasis and TIIDM: Formononetin, isolated from Trifolium pratense,  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 30/November/2017, 11.49 pm
November 30, 2017
Activation of the PD-1 pathway for Pain therapy: Glycine, a non-essential amino acid and neurotransmitter, increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 1/December/2017, 12.36 am
November 30, 2017
Show all

Introduction: What they say

A study from Department of Biology, University of Bergen, Bergen, Norway; and Univ-Lyon, CarMeN Laboratory, INSERM 1060, INRA 1397, Université Claude Bernard Lyon, INSA Lyon, Oullins, France shows that FGF19 regulates skeletal muscle mass and ameliorates muscle wasting in mice. This research paper was published, in the 26 June 2017 issue of the journal “Nature Medicine” [One of the best research journals in Biology with an I.F of 29 plus], by Prof.Ruzzin J,Bérengère B and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:   Molecular therapy for muscle atrophy and wasting: Cilostazol, a phosphodiesterase inhibitor used in the treatment of Peripheral vascular disease, increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors  genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene


From Significance of the study to Public health relevance:

Given that: (1) Muscular dystrophy/wasting is a degenerative disease; (2) Muscular dystrophy/wasting also occur due to a number of pathophysiological conditions, including cancer, denervation, disuse and fasting ; (3) there is no permanent cure for muscular dystrophy; (4) the life-long discomfort and the medical care required to alleviate pain-associated (muscle weakness) with muscular dystrophy; (5) the global economic cost spent for muscular dystrophy is enormous,there is an urgent need to find: (i) a way to rejuvenate muscle (satellite) stem cells that were lost in Muscular dystrophy; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free natural product-based drug.


What is known?

A number of studies have firmly established a role for FGF19 in metabolic diseases. However, its role in other physiological processes remains largely unknown.

Prof. Ruzzin’s research team members have recently shown that:(1) FGF19 treatment results in skeletal muscle hypertrophy; (2) treatment with physiologically equivalent level of FGF19 increases the size of human myotubes; (3) induction of FGF19 results in phosphorylation of extracellular-signal-regulated protein kinase 1/2 (ERK1/2) and the ribosomal protein S6 kinase (S6K1), a protein that promotes protein synthesis and cell growth ; (4) deletion of of ß-Klotho (KLB), a receptor of FGF19, in skeletal muscle nullifies the hypertrophic actions of FGF19; (5) treatment with FGF19 improves skeletal muscle atrophy caused by a) glucocorticoid treatment, b) obesity, and c)sarcopenia, suggesting that increasing the expression of FGF19 may prevent muscle wasting, attenuate muscular dystrophy and improve sarcopenia.


From research findings to Therapeutic opportunity:

This study suggests, for the first time, that Cilostazol, the drug used in the treatment of Peripheral vascular disease, may aid in the treatment of Muscular dystrophy.

Cilostazol, by increasing the expression of its target genes, it may increase the expression of FGF19 and its receptor ß-Klotho (KLB) (Fig. 1). Thereby, it may: (1) increase the phosphorylation of ERK1/2 and S6K1; (2) enlarge muscle fibre size; (3) increase skeletal muscle mass; (3) promote skeletal muscle hypertrophy; (4) protect muscle from atrophy and muscle wasting. Thus, pharmacological formulations encompassing “Cilostazol or its analogues, either alone or in combination with other drugs, may be used to treat muscular dystrophy and wasting (fig.1).[easy_payment currency=”USD”]

Figure 1. Mechanistic insights into how Cilostazol, by increasing the expression of FGF19 and its down stream target genes, may promote muscle hypertrophy and improve muscular dystrophy


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Cilostazol increase the expression of FGF19 to promote hypertrophy of skeletal muscle cells and attenuate muscular dystrophy?

Amount: $ 500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Molecular therapy for muscle atrophy and wasting: Cilostazol, a phosphodiesterase inhibitor used in the treatment of Peripheral vascular disease, increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors  genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 1/December/2017, 12.03 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org

Comments are closed.